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Lungsed as potential therapeutic strategy with regard to their ability to induce cell
death. We previously demonstrated that C2-ceramide generated apoptosis in bronchocarcinoma BZR cells.
We here investigated whether ceramides also target other molecules involved in cell–cell or cell–matrix
interactions during cancer progression. A SuperArray® analysis showed that ceramides modulate gene
expression after 2 h. Among deregulated genes, we observed an inhibition of the transcript coding for the
pro-metastatic enzyme MMP-2. The pharmacological inhibitor of caspases cascade, ZVAD-fmk, did not
prevent C2-ceramide-induced down-regulation of MMP-2 ruling out apoptosis as a mediator of this event,
whereas inhibition of oxidative stress using NAC conﬁrmed a role for ROS. This effect of C2-ceramide was
associated with changes in histone H3 acetylation. However, although histone deacetylase inhibitors are also
currently under investigation for their anti-tumor activity, we demonstrated here that a combined treatment
with trichostatin A abrogated both MMP-2 down-regulation and reduced invasive properties elicited by C2-
ceramide alone. Hence, this study demonstrates that besides its apoptotic effect, C2-ceramide also exhibits
anti-invasive properties, showing a dual beneﬁcial effect against cancer progression, but casts some doubt on
the use of HDAC inhibitors as combined treatment with drugs that trigger the ceramide pathway.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionTargeting ceramides has been proposed as a potential therapeutic
strategy with the aim of counteracting tumor progression. Evidence
for such proposal was based on the observation that ceramide levels
are signiﬁcantly reduced in vivo in cancer such as colon carcinoma
compared to healthy tissues [1]. Ceramides are intracellular second
messengers for a variety of cellular processes, ranging from differen-
tiation, proliferation, and apoptosis through caspase activation [2] (for
review). Most of their potential therapeutic values are linked to this
latter property, and especially to the fact that cell-permeable ceramide
analogues induce apoptosis in tumor cells such as in human lung
cancer-derived cells [3,4]. However, somewhat in contradiction withy the CNRS, and the Comité de
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l rights reserved.their pro-apoptotic activity, ceramides are also able to promotematrix
metalloproteinases (MMPs) secretion [5–7], a family of proteases
currently described to promote cancer cell invasion. Although MMP
up-regulation was demonstrated in non-cancerous cells, ceramide
effects on MMPs are intriguing and raise questions about the precise
function of ceramides in the regulation of tumor progression.
Enhancement of secretion and proteolytic activation of MMPs in
human cancer tissues represents one of the critical steps in tumor
invasion and metastasis [8–11]. MMPs constitute a family of 25
structurally related proteolytic enzymes, which are responsible for
extracellular matrix (ECM) degradation. Compared to its relatively low
rate of turnover under physiological conditions, acceleration of ECM
turnover occurs during the tissue remodelling that accompanies many
pathological processes such as inﬂammation or tumor invasion [12–
14], notably in lung tissue [15,16]. Amongmembers of this family,MMP-
2 (gelatinase A) is of particular interest since this enzyme is not only
capable of degrading several components of the basement membrane
but also can participate in cytokine turnover [17] and activation [18].
Thus, this enzyme is thought to play a pivotal function in cancer cell
invasion and inﬂammation, facilitating tumor progression. Indeed, the
invasion process involves the dispersed of epithelial cells from
neoplastic clusters followed by cell invasion of adjacent stromal
connective tissue [15,19]. As a matter of fact, MMP-2 together with
its activator MT1-MMP was found especially involved in human
bronchopulmonary carcinoma invasion in vitro and in vivo [20,21].
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the bronchopulmonary BZR cell line [3]. We here investigated the
effects of C2-ceramide on matrix-related molecules by SuperArray®
experiments. The purpose of this study was to seek potential targets
involved in cell–cell or cell–matrix interaction, and to get better
knowledge and understanding associated with the invasion mechan-
ism of short-chain ceramides on cancer. Using a highly invasive cell
line, i.e. BZR, we here evidenced that ceramides repressed MMP-2
gene expression, suggesting that in addition to their pro-apoptotic
activity, ceramides can simultaneously reduce bronchopulmonary
tumor invasion. The mechanisms involved in these anti-invasive
activities were found to be due, at least in part, to alteration of the cell
redox system and modiﬁcation of histone acetylation. Histone
deacetylase inhibitors (HDACi) are also promising anticancer agents
acting by modifying chromatin structure and thereby modulating
gene expression patterns involved in lung cancer [22]. In this setting,
this class of inhibitors could therefore represent an alternative
therapeutic approach for primary and metastatic cancer. However,
using trichostatin A (TSA) as an HDAC inhibitor, we demonstrated that
the combined effect of ceramide and TSA suppressed the beneﬁcial
effects of C2-ceramide on proMMP-2 secretion and bronchopulmon-
ary cancer-derived cell invasion.
2. Materials and methods
2.1. Cell-culture conditions
Human lung epithelial cell lines, BZR (ATCC CRL-9483) were
maintained in Dulbecco's modiﬁed Eagle's medium (DMEM) (Gibco
BRL, Life Technology) supplemented with 10% (v/v) heat-inactivated
foetal bovine serum (FBS) (Dutscher SA), 100 U/ml penicillin, 100 µg/
ml streptomycin at 37 °C, 5% CO2. For the assays, cells were seeded into
6-plates at 0.2×106 cells per well and incubated overnight. The wells
were rinsed twice with DMEM without FBS prior to treatment. Cell
viability was determined by trypan blue exclusion.
2.2. Experimental procedures
C2-ceramide, C6-ceramide or Dihydroceramide solutions (SL-100-
0005, SL-101-0005 and SL-110-0005, BIOMOL, Tebu-Bio, France) were
added to fresh culture mediumwithout FBS at t=0 and then incubated
at 37 °C for varying times.
2.3. In vitro invasion assays
50,000 cells were suspended in serum-free DMEM containing 0.2%
BSA and seeded onto membranes (tissue culture treated, 6.5 mm
diameter, 8 μm pore) coated with Matrigel (30 μg/cm2) using modiﬁed
Boyden chambers (Transwell, Costar). DMEM supplemented with 10%
FBS and 2% BSAwas used as a chemoattractant. After a 6 h incubation
period in absence or presence of effector, cells were ﬁxed with
methanol and stained using crystal violet for 15 min. Cells remaining
on the upper face of the membranes were scrapped and those on the
lower face were counted using an inverted microscope.
2.4. Zymography
Zymography in gels were performed on conditioned media.
Samples were separated by electrophoresis in a 10% SDS-PAGE
containing gelatin (1 mg/ml) as a substrate [23].
2.5. Isolation of total RNA and mRNA expression studies (RT-PCR)
Total RNA was isolated from BZR cells using the TRIzol reagent
(Invitrogen Life Technologies) following the manufacturer's recom-
mendations. Oligonucleotide primers and PCR conditionswere chosenusing the published sequences of the humanMMP-2 [24] and 18S RNA
[25]. Sequences of primers for MMP-1 and TIMP-1 were as follows:
(sense) 5′-GCTTTCCTCCACTGCTGCT-3′, (antisense) 5′-CTTGCC-
TCCCATCATTCTTC-3′, and (sense) 5′-GACGGCCTTCTGCAATTCC-3′,
(antisense) 5′-GTATAAGGTGGTCTGGTTGACTTCTG-3′, respectively.
Bands were visualized and scanned using a white/UV gel camera
Imaging densitometer, UVP (Bio-rad).
2.6. Preparation of protein extracts and quantiﬁcation
The medium overlying the cells was discarded and replaced with
ice-cold phosphate buffer saline. Cells were harvested by scrapping,
followed by centrifugation at 400 g.
2.6.1. Nuclear extract
Cells were lysed in PBS pH 7.4; 0.5% Triton X-100; 80 mM β-
glycero-phosphate; 50 mM EGTA; 15 mM MgCl2; 1 mM Na3VO4 and
protease inhibitors. Lysates were centrifuged for 20 min at 15,000 g,
and supernatants diluted in reducing SDS sample buffer. Protein
content was determined using the BCA protein quantiﬁcation kit
(Pierce, UK).
2.6.2. Histone extraction
Acid soluble histones were puriﬁed and acetone precipitated.
Precipitates were resuspended in 100 µl H2O and quantiﬁed by
spectrophotometry at 230 nm.
2.7. Western blotting of acetylated histone H3
Proteins were separated on 15% acrylamide denaturing gels and
transferred on to nitrocellulose membranes. The anti-acetyl H3 anti-
body was used at a 1:1000 dilution (Upstate, cell signalling; 06-599).
2.8. Electrophoretic mobility assay (EMSA) assay
Binding reactions were performed in 20 µl using 5 µg of nuclear
extract protein, 0.25 mg/ml poly(dI-dC).poly(dI-dC) and binding
buffer (Promega). Nuclear extracts were incubated for 20 min at
room temperature with γ32P-ATP end-labelled double-stranded
probes. The speciﬁcity of DNA-binding was assessed by competition
using commercially available consensus sequences. Samples were
electrophoresed through 6% polyacrylamide gels at a constant voltage
of 180 V. The gels were dried and autoradiographied.
2.9. Chromatin-immunoprecipitation assay
Chromatin-immunoprecipitation assay was carried out on BZR
cells untreated or treated with Ceramides (40 µM) for 2 h. ChIP
experiments were conducted as previously described [26]. Sonicated
cell pellets received either anti-acetyl-H3 antibody (1 µg/µl, Upstate)
or rabbit anti-IgG antibody (1 µg/µl, Sigma) as negative control or no
antibody (Input). Precipitated DNA was then ampliﬁed by PCR using
primers encompassing 2 sequences of the MMP-2 promoter: region
(−1357/−1158) forward primer 5′-TCTCTGGGCCATTGTCAATGTT-3′
and reverse primer 5′-TAAGCTGTGATGGGGAACTCCA-3′; region
(−130/+60) forward primer 5′-AAAGTGGAGGAGGGCGAGTAGG-3′
and reverse primer 5′-TTAAAGCCCCAGATGCGCAG-3′. Another PCR
was applied as control in the 9th intron sequence (+14321/+14497)
with forward primer 5′-TCTTGACTTTCAGCTACAGTTTGGG-3′ and
reverse primer 5′-TGTGACTTATTTCAGGCAGTGGAAT-3′. Positions are
expressed relatively to the transcriptional start site [40].
2.10. Microscopy analysis
BZR cells were incubated for 10 min in the dark at room
temperature with a solution composed of 100 µM chromomycin A3
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mounted in glycerol solution containing an antifading agent (Citiﬂuor,
Agar scientiﬁc, UK). Nuclei were examined with an MRC 1024 ES Bio-
rad confocal system mounted on a Zeiss Axioplan microscope (Zeiss,
Germany). The laser used was a 25 mW multiline argon laser
producing two major lines at 488 and 514 nm and one minor line at
456 nm. The latter was selected to excite chromomycin A3 speciﬁcally.
For each condition, a minimum of 30 nuclei was examined.
Parameters were established to obtain images with a good signal to
noise ratio and to avoid blenching.
2.11. GSH assays
GSH levels were measured by the 5,5′-dithiobis-(2-nitro-benzoic
acid) DTNB-GSSG reductase recycling, as described previously [27].
2.12. Superoxide anion production
After stimulation, BZR cells were incubated with NBT (0.5mg/ml in
phenol-free DMEM) for the indicated times. Light absorbance was
measured at 540 nm.
2.13. Transfection assays
Cells were transiently transfected with 1 µg of MMP-2-Luc
plasmid (a kind gift by Dr. Sun LY, Parke-Davis Pharmaceutical
Research, Michigan 48105) and 0.08 µg of PRLTK plasmid (Promega)
using 2 µg LipofectAMINE (Invitrogen). After exposure to ceramides,
cells were washed and lysed with a passive lysis buffer supplied with
the Dual-Luciferase reporter Assay system kit (Promega). Dual-Table 1
SuperArray® gene list analyzed in Fig. 1A (Membrane GEArrayA® EHS-013, Human extraceluciferase activities were recorded on 20 µl lysate supernatant
following the respective injections of 100 µl LAR II and 100 µl Stop
Glow reagents.
2.14. Statistical analysis
The results are expressed as means±SEM of triplicate assays and
compared with the Student's t test.
3. Results
3.1. Effects of C2-ceramide on Matrix genes expression
We ﬁrst performed a SuperArray® analysis designed to determine
the expression proﬁle of a group of genes, including matrix
metalloproteinases (MMPs), integrins, proteases and protease inhibi-
tors, all of which involved in cell–cell and cell–matrix interactions.
Speciﬁcity of ceramide effect was addressed using dihydroceramide
analogue as control, which lacks the double bond. Discrimination
analysis of mRNA expression between DH, C2- and C6-ceramide-
treated cells showed that the expression of several genes (see Table 1
for gene identiﬁcation number) were either down- or up-regulated
(Fig. 1A). Among the members of the MMP family, only MMP-1 and
MMP-2 mRNAs were detected. Two hours treatment of BZR cells with
C2- or C6-ceramide reduced the level of MMP-2 but not MMP-1mRNA
(Fig. 1B). Also TIMP-1 expression was not affected after C2-ceramide
treatment (Fig. 1B). RT-PCR experiments performed after 4 h of
treatment conﬁrmed the decrease in MMP-2 mRNA upon C2-
ceramide treatment, without eliciting any effect on MMP-1 and
TIMP-1 mRNA (Fig. 1C).llular matrix and adhesion molecules, Tebu-Bio, France)
Fig. 2. Ceramides decrease MMP-2 secretion. (A) Effects of C2-ceramide on MMP-2
secretion measured by gel zymography. BZR cells were treated with C2-ceramide
ranging from 0 to 40 µM for 6 h. (B) Kinetics of MMP-2 secretion following C2- and C6-
ceramide treatments. (C) Inﬂuence of the zVAD.fmk pan-caspase inhibitor on C2-
ceramide (40 µM)-induced MMP-2 secretion inhibition.
Fig. 1. Effects of C2- and C6-ceramides on matrix-related molecule expression. (A)
Matrix molecule expression determined by SuperArray® experiments. Genes differen-
tially regulated are pointed in the DH panel and correspond to: 14: COL18A1: Collagen,
type XVIII, alpha 1; 33: CTNNA1: Catenin (cadherin-associated protein), alpha 1,
102 kDa; 45: ITGA2B: Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex,
antigen CD41B); 46: ITGA3: Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3
receptor); 48: ITGA5: Integrin, alpha 5 (ﬁbronectin receptor, alpha polypeptide); 54:
ITGAM: Integrin, alpha M (complement component receptor 3, alpha; also known as
CD11b (p170), macrophage antigen alpha polypeptide); 57: ITGB1: Integrin, beta 1
(ﬁbronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12); 71:
LAMB1: Laminin, beta 1; 76: MMP-1: Matrix metallopeptidase 1 (interstitial
collagenase); 85: MMP-2: Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase,
72 kDa type IV collagenase); 99: SPARC: Secreted protein, acidic, cysteine-rich
(osteonectin); 103: TGFB1: Transforming growth factor, beta-induced, 68 kDa; 108:
TIMP-1: Tissue inhibitor metallopeptidase 1. (B) SuperArray® densitometric analysis of
spots detected for MMP-1, MMP-2 and TIMP-1 mRNAs. Results are expressed in
percentage relative to DH-treated cells. (C) RT-PCR analysis of MMP-1, MMP-2 and
TIMP-1 mRNA expression in BZR cells treated with 40 µM C2-ceramide for 4 h.
Ampliﬁcation of 18S RNA was used as control. PCR products were obtained with
speciﬁc primers.
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ITGA5 (integrin alpha2B and alpha5 respectively) were mainly
decreased in C2-ceramide-treated cells, whereas collagen XVIII
alpha1 chain and laminin1 beta chain gene expressions were
enhanced upon both C2 and C6-ceramide treatment (Fig. 1A).
3.2. Effects of ceramides on MMP-2 secretion from BZR cells
We then performed concentration–response experiments to study
in-depth effects of ceramide treatment on MMP-2 secretion inconditionedmedia (Fig. 2A). Under basal conditions, BZR cells secreted
the latent form of MMP-2 (proMMP-2), which was concentration-
dependently reduced upon 4 h of C2-ceramide treatment (Fig. 2A).
Time-dependent analysis of proMMP-2 secretion revealed that the C2-
ceramide inhibitory effect was an early and progressive event (Fig. 2B),
and comparison between C2- and C6-ceramide effects on proMMP-2
secretion showed barely any difference (Fig. 2B).
Although C2-ceramide triggered caspase-3 activation in BZR cells
only after a 6-h incubation period [3], we investigated the potential
implication of cell death in the reduction of MMP-2 secretion. Hence,
we compared proMMP-2 level in cells treated with C2-ceramide alone
or combined with the pan-caspase inhibitor zVAD.fmk versus control,
and found that the C2-ceramide inhibitory effect on proMMP2
secretion was not reversed by inhibition of caspase activity (Fig. 2C).
All together, these results indicate that MMP-2 down-regulation upon
ceramide treatment is an early phenomenon, independent of the pro-
apoptotic cascade.
3.3. Inﬂuence of ROS signalling pathway in ceramide inhibitory effect on
MMP-2 secretion
To determine the signalling pathway involved in MMP-2 down-
regulation upon ceramide treatment, we ﬁrst treated BZR cells with
the chemical inhibitors U0126, SB203508 and LY294002, which are
Fig. 3. ROS inhibition mediates C2-ceramide MMP-2 decrease of secretion. (A) Kinetics of ROS production in bronchial cells treated with C2-ceramide (40 µM). (B) GSH content was
measured in bronchial cells exposed to C2-ceramide (40 µM, 4 h). (C) Kinetics of MMP-2 secretion following NAC stimulation. Modiﬁcation of cell morphology was observed using
phase-contrast microscopy. (D) Effects of H2O2 supplementation on DH-, C2- and C6-ceramide effect on MMP-2 secretion.
1722 R. Debret et al. / Biochimica et Biophysica Acta 1783 (2008) 1718–1727potent inhibitors of the Erk1/2, p38 and PI3 kinase pathways
respectively. ProMMP-2-reduced secretion upon ceramide treatment
could not be reproduced nor reversed by co-treatment with these
compounds (data not shown).
We further hypothesized that the effect of ceramide on proMMP-2
expression may be due to modulation of intracellular reactive oxygen
species (ROS), another signalling pathway associated with ceramide
effects. Exposure of BZR cells to C2-ceramide led to a transient
increase of free radical superoxide anion release in BZR cells, followed
by a decrease in the intracellular ROS level (Fig. 3A). The decrease in
intracellular ROS was associated with a decrease in cellular GSH
content (Fig. 3B) corresponding to GSH consumption during ROS
metabolism. We therefore assessed the involvement of ROS in the
regulatory mechanism of proMMP-2 by treating BZR cells with NAC
(N-acetyl-L-cysteine), a ROS scavenger and GSH precursor (Fig. 3C).
Kinetics analysis showed that NAC reduced proMMP-2 secretion and
that this effect was still present after 24 h of treatment without
altering cell viability (Fig. 3C, microscopy images). To conﬁrm the
involvement of ROS depletion in proMMP-2-reduced production, wethen examined the effect of a supplementation with free radicals on
ceramide-treated cells (Fig. 3D). Pre-treatment of BZR cells with H2O2
concentration-dependently abrogated the inhibitory effect of both C2-
and C6-ceramide treatments on proMMP-2 secretion (Fig. 3D).
3.4. Effects of C2-ceramide on MMP-2 gene expression
To give a preliminary insight onmolecularmechanisms involved in
MMP-2 gene down-regulation, we ﬁrst analysed the DNA-binding
capacity of two transcription factors (AP-1, AP-2) relevant for MMP-2
gene transcription (those potential MMP-2 regulatory elements are
depicted in Fig. 4B). Gel shift experiments revealed that treatment of
BZR cells with C2-ceramide (40 µM) decreased both AP-1 and AP-2
DNA-binding compared to untreated cells (Fig. 4A). Speciﬁcity of DNA-
binding was assessed by competition using consensus sequences
speciﬁc and non-speciﬁc for these transcription factors (Fig. 4A). To
further address the genetic regulation of the MMP-2 gene, we then
transfected BZR cells with a construct containing the 5′ region
(−1659 bp) of the MMP-2 promoter coupled to a luciferase reporter
Fig. 4. C2-ceramide prevents transcription factor DNA-binding and down-regulates
MMP-2 expression. (A) C2-ceramide treatment inhibits AP-1 and AP-2 DNA-binding.
Speciﬁcity of DNA-binding was assessed by speciﬁc (Spe) and non-speciﬁc (NSpe)
competition experiments. (B) C2-ceramide reduces reporter gene activity coupled to
MMP-2 promoter. BZR cells were transfected with the full length MMP-2 promoter.
After an overnight transfection, cells were treated with C2-ceramide (40 µM) for
6 h and luciferase activity measured relative to a control of transfection efﬁciency
(pRL-TK plasmid).
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promoter was repressed upon C2-ceramide treatment (Fig. 4B).
3.5. C2-ceramide-induced MMP-2 down-regulation via HDAC inhibition
HDAC inhibitors have been reported to induce ROS production
[28]. We then investigated the role of chromatin remodelling in the
down-regulation of MMP-2 upon ceramide treatment (Fig. 5). Hence,
we ﬁrst investigated the effects of C2-ceramide treatment on
chromatin condensation, as monitored by staining with the inter-
calating dye chromomycin A3. Fig. 5A shows that nuclear condensa-
tion advanced gradually during ceramide treatment, and became
apparent as early as 1 h. We then analysed the inﬂuence of C2-
ceramide on histone acetylation by Western-blot analysis, and
showed that histone H3 acetylationwas decreased in BZR cells treated
with C2-ceramide compared to untreated cells (Fig. 5B). We further
examined nuclear condensation and histone H3 acetylation with
MMP-2 transcription by ChIP assay (Fig. 5C). Chromatin fragments
from cells treated with dihydroceramide as control or with C2-
ceramide were immunoprecipitated with an anti H3-acetylatedantibody versus non-speciﬁc antibody (IgG) and theMMP-2 promoter
was examined by RT-PCR with primers amplifying the (−1357/−1158)
region encompassing the AP-1 binding motif, and the (−130/+60)
sequence encompassing the AP-2 binding site. Analysis of ChIP
experiment results demonstrated that C2-ceramide treatment
reduced H3-acetylation level by approximately 60% within the AP-1
region of the MMP-2 promoter, whereas signiﬁcant variation was
observed neither at the AP-2 nor at the control sites delineated in the
9th intron of the MMP-2 gene (Fig. 5C).
3.6. TSA counteracts the C2-ceramide inhibitory effect on BZR cell
invasion
We then extended our observation on chromatin remodelling and
examined the effects of a pre-treatment of BZR cells with TSA, an
HDAC inhibitor, on the level of secreted proMMP-2 in cells co-treated
with or without C2-ceramide. Treatment with TSA alone did not
signiﬁcantly affect secreted proMMP-2 level, whereas combined to
C2-ceramide, TSA partially rescued proMMP-2 secretion (Fig. 6A).
MMP-2 expression from BZR cells has been associated with aggressive
behaviour; we thus wondered whether C2-ceramide effects could
alter BZR cell migration through Transwell membranes coated with
Matrigel (Fig. 6B). The invasive properties of BZR cells were
signiﬁcantly inhibited by treatment with C2-ceramide, whereas
treatment with TSA did not affect cell migration. However, combined
with C2-ceramide, pre-treatment with TSA abolished the inhibitory
effect induced by C2-ceramide on BZR cell migration (Fig. 6B).
4. Discussion
In this study, SuperArray® experiments were conducted as a
starting point to delineate awider effect of short-chain ceramides on a
group of genes involved in cancer invasion. Among the panel of altered
genes, we found that ceramides inhibited MMP-2 expression.
Determination of MMP-2 down-regulation mechanisms emphasized
the role of ROS and chromatin remodelling in the bronchocarcinoma
BZR cell invasive properties. Such ﬁnding therefore provides enlarged
evidence for the therapeutic potential of the ceramide pathway, and is
in setting with in vivo experiments using MMP-2 deﬁcient mice,
which established a relationship between this protease expression
and lung cancer progression [29]. Accordingly, in vitro analysis of
highly invasive bronchial BZR cells also demonstrated a strong
correlation between invasiveness and MMP-2 activity [19,30,31].
Reduced MMP-2 expression in BZR cells upon ceramide stimulation
was independent of the pro-apoptotic property of this compound
since MMP-2 down-regulation was observed as early as 2 h following
ceramide treatment (SuperArray®), whereas caspase-3 activation did
not occur before 6 h of incubation [3]. Moreover, the pan-caspase
inhibitor zVAD-fmk largely reduced apoptosis induced by C2-
ceramides [3], but failed to affect the C2-ceramide-decreased
proMMP-2 secretion. Hence, combined with our previous study [3],
ceramides decrease bronchopulmonary cell invasiveness both by
affecting mechanisms that lead to MMP-2 down-expression and by
triggering apoptosis, therefore underscoring a dual beneﬁcial effect of
C2-ceramide on bronchocarcinoma cancer progression.
Hence, we did not conﬁrm previous results showing that apoptosis
is a key event in initiating extracellular matrix degradation [32]. If in
some models, ceramide-induced apoptosis may occur in concert with
altered expression of gene related to malignant phenotype [7,33],
Preaux et al. found that induction of apoptosis was not associated with
MMP-2 mRNA modulation in hepatic myoﬁbroblasts [34]. Then,
coupling of the two phenomena may be more complicated than
originally thought, andmight be cell type speciﬁc, if not dependent on
the tumorogenic character of the cells. Furthermore, not all genes
related to matrix molecules were down-regulated following ceramide
stimulation. Specially, among members of the MMP family, neither
Fig. 5. Histone acetylation regulates MMP-2 secretion. (A) Confocal analysis of nuclear condensation. Time–response effects of C2-ceramide (40 µM). (B) Inhibition of histone H3
acetylation upon C2-ceramide treatment observed byWestern blotting with speciﬁc antibody. (C) Chromatin immuno-precipitation assay on theMMP-2 promoter following DH and
C2-ceramide treatment (40 µM, 2 h).
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mRNA levels were altered. Then as stated above, speciﬁc targeting of
MMP-2 by ceramide treatment might be cell type speciﬁc since C2-
ceramide increased MMP-1 in ﬁbroblasts [6], and MMP-1, -3, and -13
expression in chondrocytes [7]. Then, depending on the cell type,
different mechanisms might be implicated in these genes expression
following C2-ceramide treatment. In BZR cells, upon C2-ceramide
treatment, both MMP-2 mRNA level and promoter activity decreased
by approximately 30%, whereas reduction in protein level was more
pronounced. This suggests that multiple mechanisms are involved in
MMP-2 decreased secretion. One possible hypothesis would be
internalisation of the proMMP-2 protein by formation of complex
with LRP, a low density lipoprotein receptor-related protein which
mediates the endocytic clearance of various soluble proteases [35].
This observation argues against a global inhibition of cellular activity
upon C2-ceramide stimulation. Indeed, besides MMP genes, COL18A1
chain and laminin1 beta chain genes were up-regulated. Interestingly,
it has been reported that an over-expression of the COL18A1 gene is
correlated to tumorogenesis resistance driven by the anti-angiogenicproperties of endostatin, aMr 20,000 proteolytic fragment of collagen
XVIII [36]. Not only are these observations in favour of a speciﬁc
mechanism involved inMMP-2 down-regulation preferably to a global
inhibitory mechanism, but inhibition by C2-ceramides of MMP-2
expression might represent an alternative therapeutic strategy to
counteract tumor progression in cancer cells resistant to apoptosis.
Upon ceramide stimulation, a decrease in ROS production
corresponding to GSH consumption was associated with reduced
MMP-2 gene expression, which is in agreement with the former
documented relationship between increased ceramide production
and decreased GSH levels in airway epithelial cells [37–39]. Accord-
ingly, the antioxidant NAC mimicked ceramide effects on MMP-2
expression. However, in our model, C2-ceramide induced apoptosis
and down-regulated MMP-2 expression, whereas NAC treatment did
not induce cell death. A potential explanation would be that increase
of ROS in the early time point might be related to apoptosis as already
documented [28], whereas MMP-2 down-regulation would be
inherent to ROS decrease (Fig. 7). In this setting, Gutierrez et al.
recently demonstrated that ceramide-induced apoptosis in cervical
Fig. 6. Trichostatin A counteracts C2-ceramide effects. (A) Co-treatment of BZR cells
with the histone deacetylase inhibitor trichostatin A (TSA) counteracts C2-ceramide
inhibitory effect on MMP-2 secretion measured by gel zymography. Values represents
mean±SEM (n=3) and quantitative analyses are showed in histogram. (B) Effect of
C2-ceramide and TSA on BZR invasion properties. Tumor cell migration was
measured on Transwell membranes. Modulation of BZR invasion was determined
by cell counting. Values represent mean±SEM (n=4) and quantitative analyses are
showed in the histogram.
Fig. 7. Dual effects of C2-ceramide on BZR cell invasiveness. C2-ceramide induced
apoptosis and down-regulated MMP-2 expression. Increased ROS level in the early time
point might be related to a delayed apoptosis mechanism, whereas MMP-2 down-
regulation would precede the apoptotic phenomenon and would be inherent to ROS
and decrease in histone acetylation.
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ROS [40]. Then, this is consistent with the hypothesis that signal
transduction pathways involved in the regulation of apoptosis and in
the regulation of MMP-2 expression are distinct.
While the MMP-2 gene has been genuinely considered as
refractory to modulation, it is now recognized that the expression of
this gene can be either up- or down-modulated depending on the
stimuli [41–44]. Analysis of the MMP-2 promoter sequence revealed
several potential binding sites for transcription factors such as AP-1,
AP-2, p53, and SP-1. Actually, only a few of these transcription factors
may take part in either the constitutive or up/down-regulation of this
enzyme. AP-1 DNA-binding was effectively reduced in ceramide-
treated cells. However, only one report speciﬁcally deﬁned this
transcription factor as a regulator of this gene under physiopatholo-
gical conditions [45]. Despite ceramides beingwell-known inducers of
apoptosis, it was unlikely that p53 participated in the MMP-2
promoter repression. Indeed, it has been evidenced that only the
wild type form of p53 could activate the MMP-2 promoter, and not
repress it, whereas the p53 mutant form commonly found in human
cancer is ineffective as a transcription factor [41,46]. Accordingly, we
found no modiﬁcation of p53 expression in our cells following
ceramide treatment (data not shown). Two SP-1 and one AP-2 sites
within the proximal region of the promoter have been shown to be
essential for the constitutive MMP-2 promoter activity [43,47]. AP-2DNA-binding was also reduced upon ceramide treatment, whereas
using a speciﬁc SP-1 inhibitor (WP631), we found that this family of
transcription factors was not involved in MMP-2 promoter down-
regulation (data not shown). However, the precise role of AP-2 in
MMP-2 gene regulation still needs to be delineated; while several
studies effectively proposed AP-2 as a requisite element drivingMMP-
2 expression [43,47], other studies showed that AP-2 dominant-
negative expressing cell displayed increased MMP-2 expression [48].
Hence, although there are differences in intensity betweenmRNA, AP-
1/AP-2 DNA-binding and reporter gene activity, taking all together our
results show that C2-ceramide treatment down-regulates the MMP-2
gene expression. These discrepancies could be related both i) to the
involvement of different signalling cascades controlling transcription
factors activity and ii) to the fact that the precise DNA sequences
utilised by the MMP-2 promoter and the nucleosomal context in
transient reporter assays may account for the differences seen
between with the native mRNA expression.
Alternative approaches for a number of pathologies, including
cancer, are to modulate MMP genes through epigenetic mechanisms.
Transcription factor activity is also regulated by chromatin structure
[49], whose alteration plays an important role in cancer progression
and gene transcription such as MMP-2 gene [47]. In this setting, the
high level of acetylated histone H3 observed at the MMP-2 promoter
level in untreated BZR would thereby facilitate accessibility of
transcription factors such as AP-1 and AP-2, explaining the constitu-
tive expression ofMMP-2 gene. Consequently, the observed reduction
of histone H3 acetylation upon C2-ceramide treatment was also
associated with decreased expression of MMP-2 gene. This effect was
partly inhibited by a co-treatment with TSA, implicating HDAC
activation in ceramide-mediated MMP-2 down-regulation. Increasing
evidence suggest that epigenetic modiﬁcations of histone are one of
the key mechanisms in the regulation of gene transcript [50]. For
instance, acetylation affects many protein functions including
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stability or to retain in the nucleus, all of these processes could be
important for recruitment of remodelling complexes to chromatin [for
review, 51,52]. Of interest in our study, it has been shown that c-Jun
trans-activating potential and DNA-binding activity is mediated by its
dissociation from an inhibitory complex containing HDAC3, a class 1
HDAC [53]. Therefore, it could be postulated that C2-ceramide effects
on MMP-2 gene repression are indirect through repression of
transcription factor activity such as AP-1 by the induction of HDAC
for instance, and that TSA could relieve the repressor, leading to an
increase in transcription activation by a de-repression mechanism as
proposed by Weiss et al. [53], thus reversing C2-ceramide effects on
MMP-2 gene expression. To substantiate such hypothesis, inhibition of
AP-1 DNA-binding following C2-ceramide treatment was reversed
when BZR cells were co-treated with TSA (data not shown). Then, our
results are in agreement with data showing that TSA promotes
cancer invasion through activation of uPA, an upstream activator of
MMPs [54]. Conversely, a recent study performed on lung adeno-
carcinoma cells (A549) showed that another HDAC inhibitor (FK228)
negatively regulated MMP-2 and MMP-9 expression [22]. These
differential effects might be due to cell type or to HDAC inhibitor
speciﬁcities, raising the question of the use of HDAC inhibitors as
combined treatments.
In conclusion, we have demonstrated that C2-ceramide reduced
histone acetylation leading to chromatin condensation and therefore
to speciﬁc gene silencing such as MMP-2, providing new insights into
the mechanism of ceramide action in the invasion process. Together,
with apoptosis induction, such dual beneﬁcial effect of C2-ceramides
that occurs in the same cell type underscores its therapeutic potential.
However, in line with the corresponding effects onMMP-2 expression,
in vitro matrigel invasion assays showed that the C2-ceramide-
induced inhibition of invasion was partly reversed by the HDAC
inhibitor TSA. Annihilation effect resulting from such combined
treatments in vitro could explain part of the unresponsiveness of bi-
or multi-therapeutical approaches.
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